Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 31;25(1):2356820.
doi: 10.1080/15384047.2024.2356820. Epub 2024 May 27.

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Julia Palecki  1 , Amman Bhasin  1 , Andrew Bernstein  1 , Patrick J Mille  2 , William J Tester  2 , Wm Kevin Kelly  2 , Kevin K Zarrabi  2
Affiliations
Review

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Julia Palecki et al. Cancer Biol Ther. .

Abstract

Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as well as immune effector cells, thus promoting an immune response against cancer cells. Prostate cancer is rich in tumor associated antigens such as, but not limited to, PSMA, PSCA, hK2, and STEAP1 and there is strong biologic rationale for employment of T-cell redirecting BiTEs within the prostate cancer disease space. Early generation BiTE constructs employed in clinical study have demonstrated meaningful antitumor activity, but challenges related to drug delivery, immunogenicity, and treatment-associated adverse effects limited their success. The ongoing development of novel BiTE constructs continues to address these barriers and to yield promising results in terms of efficacy and safety. This review will highlight some of most recent developments of BiTE therapies for patients with advanced prostate cancer and the evolving data surrounding BiTE constructs undergoing clinical evaluation.

Keywords: Bispecific antibody; PSMA; Prostate cancer; STEAP1; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–12. doi:10.14740/wjon1191. - DOI - PMC - PubMed
    1. Surveillance Research Program, National Cancer Institute SEER*Stat software . 2023. https://seer.cancer.gov/statfacts/html/prost.html.
    1. Rosario E, Rosario DJ.. Localized prostate cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
    1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262. doi:10.1016/j.eururo.2020.09.042. - DOI - PubMed
    1. Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR. The long-term risks of metastases in men on active surveillance for early stage prostate cancer. J Urol. 2020;204(6):1222–1228. doi:10.1097/JU.0000000000001313. - DOI - PubMed

MeSH terms